Saint-Herblain (France), December 21, 2018 – Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its chikungunya vaccine candidate, VLA1553.